Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2006 | 1 | 2 | 103-118

Article title

Is radiocontrast-induced nephropathy avoidable? The scientific evidence in 2006


Title variants

Languages of publication



Due to the wide use of radiocontrast agents (RCA) in modern radiology and interventional cardiology, the incidence of radiocontrast-induced nephropathy (RCIN) is increasing. The risk factors for RCIN are primarily pre-existing (even mild) renal dysfunction, diabetes mellitus, absolute or relative hypovolemia, nephrotoxic drugs, etc., particularly in elderly patients. The presence of these risk factors seems to be more important than the type of contrast agent used. To date, there are several certainties and controversies in the prevention of RCIN. Hydration with normal saline and/or bicarbonate administration pre-and post-intervention is certainly useful. Though controversial, N-Acetylcysteine administration may be still advisable. Recent investigations showed the benefits of aminophylline/theophylline administration in RCA-induced renal tubular toxicity. Conventional hemodialysis cannot prevent RCIN, but may potentially aggravate renal dysfunction through hemodynamic instability. “High-flux” hemodialysis and hemodiafiltration may contribute efficiently to RCIN prevention, but systematic use of these modern dialysis techniques is limited by high costs and availability. The authors review - in a systematic manner, and in the perspective of evidence-based medicine - the most important data from literature concerning the prevention of RCIN.










Physical description


1 - 6 - 2006
1 - 6 - 2006


  • Nephrology Clinic, “Dr. C. I. Parhon” University Hospital, 700503, Iasi, Romania
  • Nephrology Clinic, “Dr. C. I. Parhon” University Hospital, 700503, Iasi, Romania
  • Nephrology Clinic, “Dr. C. I. Parhon” University Hospital, 700503, Iasi, Romania


  • [1] P.A. McCullough and K.R. Sandberg: “Epidemiology of contrast-induced nephropathy”, Rev. Cardiovasc. Med., Vol. 4(Suppl 5), (2003), pp. S3–9.
  • [2] L. Gruberg, R. Mehran, G. Dangas et al.: “Acute renal failure requiring dialysis after percutaneous coronary interventions”, Catheter Cardiovasc. Interventions, Vol. 52, (2001), pp. 409–416. http://dx.doi.org/10.1002/ccd.1093[Crossref]
  • [3] P.S. Parfrey, S.M. Griffiths, B.J. Barrett et al.: “Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study”, N. Eng. J. Med., Vol. 320, (1989), pp. 143–149. http://dx.doi.org/10.1056/NEJM198901193200303[Crossref]
  • [4] M.R. Rudnick, J.S. Berns, R.M. Cohen et al.: “Contrast media-associated nephrotoxicity”, Curr. Opin. Nephrol. Hypertens., Vol. 5, (1996), pp. 127–133. [Crossref]
  • [5] P.A. McCullough, R. Wolyn, L.L. Rocher et al.: “Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality”, Am. J. Med., Vol. 103, (1997), pp. 368–375. http://dx.doi.org/10.1016/S0002-9343(97)00150-2[Crossref]
  • [6] P.O. Joachimsson, E. Ståhle, S.O. Nyström et al.: “Incidence of acute renal failure in open heart surgery”, J. Cardiothoracic Anesthesy, Vol. 3(Suppl 1), (1989), p. 58. http://dx.doi.org/10.1016/0888-6296(89)90801-6[Crossref]
  • [7] L.G. Andersson, R. Ekroth, L.E. Bratteby et al.: “Acute renal failure after coronary surgery-a study of incidence and risk factors in 2009 consecutive patients”, Thorac. Cardiovasc. Surg., Vol. 41, (1993), pp. 237–241. http://dx.doi.org/10.1055/s-2007-1013861[Crossref]
  • [8] E.M. Levy, C.M. Viscoli, R.I. Horwitz: “The effect of acute renal failure on mortality. A cohort analysis”, J. Am. Med. Assoc., Vol. 275, (1996), pp. 1489–1494. http://dx.doi.org/10.1001/jama.275.19.1489[Crossref]
  • [9] G. Rialp, A. Roglan, A.J. Betbesé et al.: “Prognostic indexes and mortality in critically ill patients with acute renal failure treated with different dialytic techniques”, Ren. Fail., Vol. 18, (1996), pp. 667–675. [Crossref]
  • [10] G.M. Chertow, J.M. Lazarus, C.L. Christiansen et al.: “Preoperative renal risk stratification”, Circulation, Vol. 95, (1997), pp. 878–884.
  • [11] L. Gruberg, G.S. Mintz, R. Mehran et al.: “The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency” J. Am. Coll. Cardiol., Vol. 36, (2000), pp. 1542–1548. http://dx.doi.org/10.1016/S0735-1097(00)00917-7[Crossref]
  • [12] C.L. Manske, J.M. Sprafka, J.T. Strony et al.: “Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography”, Am. J. Med., Vol. 89, (1990), pp. 615–620. http://dx.doi.org/10.1016/0002-9343(90)90180-L[Crossref]
  • [13] E.C. Keeley and C.L. Grines: “Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases”, J. Am. Coll. Cardiol., Vol. 32, (1998), pp. 1861–1865. http://dx.doi.org/10.1016/S0735-1097(98)00497-5
  • [14] P.B. Persson and A. Patzak: “Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration”, Nephrol. Dial. Transplan., Vol. 20, (2005), pp. 2–5. http://dx.doi.org/10.1093/ndt/gfh1066[Crossref]
  • [15] S. Detrenis, M. Meschi, S. Musini et al.: “Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art”, Nephrol. Dial. Transplan., Vol. 20, (2005), pp. 1542–1550. http://dx.doi.org/10.1093/ndt/gfh868[Crossref]
  • [16] M.R. Rudnick, S. Goldfarb, L. Wexler et al.: “Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study”, Kidney Int., Vol. 47, (1995), pp. 254–261. [Crossref]
  • [17] N. Chalmers and R.W. Jackson: “Comparison of iodixanol and iohexol in renal impairment”, Br. J. Radiol., Vol. 72, (1999), pp. 701–3.
  • [18] P. Aspelin, P. Aubry, S.G. Fransson et al.: “Nephrotoxic effects in high-risk patients undergoing angiography”, N. Eng. J. Med., Vol. 348, (2003), pp. 491–499. http://dx.doi.org/10.1056/NEJMoa021833[Crossref]
  • [19] C. Briguori, F. Manganelli, P. Scarpato et al.: “Acetylcysteine and contrast agent-associated nephrotoxicity”, J. Am. Coll. Cardiol., Vol. 40, (2002), pp. 298–303. http://dx.doi.org/10.1016/S0735-1097(02)01958-7[Crossref]
  • [20] W. Huber, K. Ilgmann, M. Page et al.: “Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study”, Radiology, Vol. 223, (2002), pp. 772–779.
  • [21] C.P. Taliercio, R.E. Vlietstra, D.M. Ilstrup et al.: “A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography”, J. Am. Coll. Cardiol., Vol. 17, (1991), pp. 384–390. http://dx.doi.org/10.1016/S0735-1097(10)80103-2[Crossref]
  • [22] J. Kay, W.H. Chow, T.M. Chan et al.: “Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial”, J. Am. Med. Assoc., Vol. 289, (2003), pp. 553–558. http://dx.doi.org/10.1001/jama.289.5.553[Crossref]
  • [23] J.B. Oldemeyer, W.P. Biddle, R.L. Wurdeman et al.: “Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography”, Am. Heart J., Vol. 146, (2003), p. E23. http://dx.doi.org/10.1016/S0002-8703(03)00511-8[Crossref]
  • [24] J.D. Durham, C. Caputo, J. Dokko et al.: “A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography”, Kidney Int., Vol. 62, (2002), pp. 2202–2207. http://dx.doi.org/10.1046/j.1523-1755.2002.00673.x[Crossref]
  • [25] F. Boccalandro, M. Amhad, R.W. Smalling et al.: “Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast”, Catheter Cardiovasc. Interventions, Vol. 58, (2003), pp. 336–341. http://dx.doi.org/10.1002/ccd.10389[Crossref]
  • [26] C.S. Baker, A. Wragg, S. Kumar et al.: “A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study”, J. Am. Coll. Cardiol., Vol. 41, (2003), pp. 2114–2118. http://dx.doi.org/10.1016/S0735-1097(03)00487-X[Crossref]
  • [27] B.D. Bader, E.D. Berger, M.B. Heede et al.: “What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?”, Clin. Nephrol., Vol. 62, (2004), pp. 1–7.
  • [28] C. Mueller, G. Buerkle, H.J. Buettner et al.: “Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty”, Arch. Intern. Med., Vol. 162, (2002), pp. 329–336. http://dx.doi.org/10.1001/archinte.162.3.329[Crossref]
  • [29] G.J. Merten, W.P. Burgess, L.V. Gray et al.: “Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial”, J. Am. Med. Assoc., Vol. 291, (2004), pp. 2328–2334. http://dx.doi.org/10.1001/jama.291.19.2328[Crossref]
  • [30] R. Solomon, C. Werner, D. Mann et al.: “Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents”, N. Eng. J. Med., Vol 331, (1994), pp. 1416–1420. http://dx.doi.org/10.1056/NEJM199411243312104[Crossref]
  • [31] S. Fishbane, J.H. Durham, K. Marzo et al.: “N-acetylcysteine in the prevention of radiocontrast-induced nephropathy”, J. Am. Soc. Nephrol., Vol. 15, (2004), pp. 251–260. http://dx.doi.org/10.1097/01.ASN.0000107562.68920.92[Crossref]
  • [32] M. Tepel, M. van der Giet, C. Schwarzfeld et al.: “Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine”, N. Eng. J. Med., Vol. 343, (2000), pp. 180–184. http://dx.doi.org/10.1056/NEJM200007203430304[Crossref]
  • [33] A.V. Kshirsagar, C. Poole, A. Mottl et al.: “N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials”, J. Am. Soc. Nephrol., Vol. 15, (2004), pp. 761–769. http://dx.doi.org/10.1097/01.ASN.0000116241.47678.49[Crossref]
  • [34] K.E. Burns, M.W. Chu, R.J. Novick et al.: “Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial”, J. Am. Med. Assoc., Vol. 294, (2005), pp. 342–350. http://dx.doi.org/10.1001/jama.294.3.342[Crossref]
  • [35] J.H. Ix, C.E. McCulloch, G.M. Chertow: “Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis”, Nephrol. Dial. Transpl., Vol. 19, (2004), pp. 2747–2753. http://dx.doi.org/10.1093/ndt/gfh468[Crossref]
  • [36] H. Madyoon: “Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients”, Rev. Cardiovasc. Med., Vol. 2, (2001), pp. S26–30. http://dx.doi.org/10.1016/S1522-1865(00)00038-X[Crossref]
  • [37] G.W. Stone, P.A. McCullough, J.A. Tumlin et al.: “Fenoldopan mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial”, J. Am. Med. Assoc., Vol. 290, (2003), pp. 2284–2291. http://dx.doi.org/10.1001/jama.290.17.2284[Crossref]
  • [38] C. Briguori, A. Colombo, F. Airoldi et al.: “N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity”, J. Am. Coll. Cardiol., Vol. 44, (2004), pp. 762–765. http://dx.doi.org/10.1016/j.jacc.2004.04.052[Crossref]
  • [39] T.M. Ng, S.W. Shurmur, M. Silver et al.: “Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN)”, Int. J. Cardiol., (2005).
  • [40] S.K. Morcos, H.S. Thomsen and J.A. Webb: “Dialysis and contrast media”, Eur. Radiol., Vol. 12, (2002), pp. 3026–3030.
  • [41] B. Vogt, P. Ferrari, C. Schönholzer et al.: “Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful”, Am. J. Med., Vol. 111, (2001), pp. 692–698. http://dx.doi.org/10.1016/S0002-9343(01)00983-4[Crossref]
  • [42] H. Frank, D. Werner, V. Lorusso et al.: “Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure”, Clin. Nephrol., Vol. 60, (2003), pp. 176–182.
  • [43] W. Huber, B. Jeschke, B. Kreymann et al.: “Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review”, Invest. Radiol., Vol. 37, (2002), pp. 471–481. http://dx.doi.org/10.1097/00004424-200209000-00001[Crossref]
  • [44] H.S. Thomsen: “How to avoid CIN: guidelines from the European Society of Urogenital Radiology”, Nephrol. Dial. Transplant., Vol. 20, (2005), pp. 118–122.
  • [45] R. Schindler, C. Stahl, S. Venz et al.: “Removal of contrast media by different extracorporeal treatments”, Nephrol. Dial. Transplant., Vol. 16, (2001), pp. 1471–1474. http://dx.doi.org/10.1093/ndt/16.7.1471[Crossref]
  • [46] T. Lehnert, E. Keller, K. Gondolf et al.: “Effect of haemodialysis after contrast medium administration in patients with renal insufficiency”, Nephrol. Dial. Transplant., Vol. 13, (1998), pp. 358–362. [Crossref]
  • [47] G. Marenzi, I. Marana, G. Lauri et al.: “The prevention of radiocontrast-agent-induced nephropathy by hemofiltration”, N. Eng. J. Med., Vol. 349, (2003), pp. 1333–1340. http://dx.doi.org/10.1056/NEJMoa023204[Crossref]
  • [48] C.M. Erley, B.D. Bader, E.D. Berger et al.: “Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients”, Nephrol. Dial. Transplant., Vol. 19, (2004), pp. 2526–2531. http://dx.doi.org/10.1093/ndt/gfh272[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.